Satyajit Kosuri to Hematologic Neoplasms
This is a "connection" page, showing publications Satyajit Kosuri has written about Hematologic Neoplasms.
Connection Strength
1.231
-
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Nov; 23(11):2004-2011.
Score: 0.472
-
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023 02 28; 7(4):549-554.
Score: 0.174
-
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
Score: 0.174
-
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. J Clin Invest. 2020 12 01; 130(12):6668-6676.
Score: 0.149
-
COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia. 2020 10; 34(10):2809-2812.
Score: 0.146
-
Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. Biol Blood Marrow Transplant. 2017 Jun; 23(6):965-970.
Score: 0.115